Thesis icon

Thesis

A fluorogenic hypoxia-activated prodrug strategy for targeted compound delivery and imaging of tumours

Abstract:

Hypoxia, a common feature in solid tumours, is associated with aggressive phenotypes, decreased genomic stability, and with increased resistance to all forms of cancer therapy. The significant differences between the hypoxic microenvironment, and normal tissues, present a therapeutic opportunity through the design of bioreductive hypoxia-activated prodrugs (HAPs). This strategy aids the selective delivery of chemotherapeutics to hypoxic regions, reducing their effects in non-hypoxic tissue...

Expand abstract

Actions


Access Document


Files:

Authors


More by this author
Division:
Societies Other & Companies
Department:
Gray Cancer Institute
Department:
University of Oxford
Role:
Author

Contributors

Role:
Supervisor
Role:
Supervisor
Medical Research Council UK More from this funder
Cancer Research UK More from this funder
Type of award:
DPhil
Level of award:
Doctoral
Awarding institution:
University of Oxford
UUID:
uuid:f3084a0e-1665-4442-955d-82ba6e5b321f
Deposit date:
2016-12-03

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP